July 7, 2011
Aeterna Zentaris Announces Poster Presentation of Phase 1/2 Results for AEZS-108 in Prostate Cancer at Upcoming European Society of Medical Oncology Congress
QUÃ“°BEC CITY, July 7, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that an abstract on
its anticancer compound, AEZS-108, has been accepted and will be
presented during a poster session at the upcoming European Society of
Medical Oncology Congress to be held September 23-27, 2011, at the
Stockholm International Fairs in Stockholm, Sweden. AEZS-108, a
targeted cytotoxic peptide conjugate, is currently in a Phase 1/2
program in prostate and bladder cancer, and has successfully completed
Phase 2 trials in endometrial and ovarian cancer.
Abstract: "A Phase I/II Trial of AEZS-108 (AN-152) in Castration-and Taxane-Resistant Prostate Cancer", S. V. Liu, A. V. Schally, T. Dorff, S. Groshen, D. Hawes, D. Quinn, Y.C. Tai, N. L. Block, J. Engel, and J. Pinski. Presenter: Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California Date and time: Sunday, September 24, 2011, 2:00 p.m. (local time) Venue: Stockholm International Fairs, Stockholm, Sweden
molecule composed of a synthetic peptide carrier and a well-known
chemotherapy agent, doxorubicin. Phase 2 studies for the treatment of
endometrial and ovarian cancer have been successfully completed, and
Phase 1/2 trials are being conducted in prostate and bladder cancer.
AEZS-108 is the first intravenous drug in a clinical study that directs
the chemotherapy agent specifically to LHRH-receptor expressing tumors,
resulting in more targeted treatment with less damage to healthy
tissue. AEZS-108 has been granted orphan-drug designation by the FDA
and orphan medicinal product designation from the EMA for the treatment
of ovarian cancer. Aeterna Zentaris owns the worldwide rights to
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, multiple myeloma, endometrial, ovarian, prostate
and bladder cancer. The Company's innovative approach of "personalized
medicine" means tailoring treatments to a patient's specific condition
and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn
from its proprietary discovery unit providing the Company with constant
and long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.